ALK Inhibitors for Acquired Resistance: Zykadia and Alectinib episode artwork

EPISODE · Feb 18, 2016 · 3 MIN

ALK Inhibitors for Acquired Resistance: Zykadia and Alectinib

from GRACEcast · host cancerGRACE Meetings

Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.

Episode metadata supplied by the publisher feed · Published Feb 18, 2016

Embed this episode

NOW PLAYING

ALK Inhibitors for Acquired Resistance: Zykadia and Alectinib

0:00 3:44

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of GRACEcast?

This episode is 3 minutes long.

When was this GRACEcast episode published?

This episode was published on February 18, 2016.

Can I download this GRACEcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!